LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 23.5
(1.29%)
TWD 23.5
(1.29%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 361 Thousand TWD | -56.82% |
| 2022 | 836 Thousand TWD | 0.0% |
| 2021 | - TWD | -100.0% |
| 2020 | 1.28 Million TWD | -37.4% |
| 2019 | 2.04 Million TWD | 0.0% |
| 2018 | - TWD | 0.0% |
| 2017 | - TWD | 0.0% |
| 2016 | - TWD | -100.0% |
| 2015 | 12.21 Million TWD | -96.38% |
| 2014 | 337.88 Million TWD | -3.46% |
| 2013 | 350 Million TWD | 47.93% |
| 2012 | 236.59 Million TWD | 0.0% |
| 2011 | - TWD | 0.0% |
| 2010 | - TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 121 Thousand TWD | 0.0% |
| 2024 Q3 | - TWD | 0.0% |
| 2024 Q1 | 241 Thousand TWD | 0.0% |
| 2023 Q2 | 600 Thousand TWD | -16.43% |
| 2023 FY | 361 Thousand TWD | -56.82% |
| 2023 Q1 | 718 Thousand TWD | -14.11% |
| 2023 Q4 | 361 Thousand TWD | -24.79% |
| 2023 Q3 | 480 Thousand TWD | -20.0% |
| 2022 FY | 836 Thousand TWD | 0.0% |
| 2022 Q4 | 836 Thousand TWD | -12.37% |
| 2022 Q3 | 954 Thousand TWD | 0.0% |
| 2022 Q2 | - TWD | 0.0% |
| 2022 Q1 | - TWD | 0.0% |
| 2021 Q1 | 856 Thousand TWD | -33.23% |
| 2021 Q4 | - TWD | 0.0% |
| 2021 Q3 | - TWD | -100.0% |
| 2021 FY | - TWD | -100.0% |
| 2021 Q2 | 429 Thousand TWD | -49.88% |
| 2020 FY | 1.28 Million TWD | -37.4% |
| 2020 Q4 | 1.28 Million TWD | -24.9% |
| 2020 Q3 | 1.7 Million TWD | 45.9% |
| 2020 Q1 | 1.47 Million TWD | -28.22% |
| 2020 Q2 | 1.17 Million TWD | -20.41% |
| 2019 FY | 2.04 Million TWD | 0.0% |
| 2019 Q4 | 2.04 Million TWD | 143.23% |
| 2019 Q2 | 1.25 Million TWD | 35.71% |
| 2019 Q1 | 927 Thousand TWD | 0.0% |
| 2019 Q3 | 842 Thousand TWD | -33.07% |
| 2018 Q3 | - TWD | 0.0% |
| 2018 Q1 | - TWD | 0.0% |
| 2018 FY | - TWD | 0.0% |
| 2018 Q4 | - TWD | 0.0% |
| 2018 Q2 | - TWD | 0.0% |
| 2017 Q3 | - TWD | 0.0% |
| 2017 Q2 | - TWD | 0.0% |
| 2017 Q1 | - TWD | 0.0% |
| 2017 FY | - TWD | 0.0% |
| 2017 Q4 | - TWD | 0.0% |
| 2016 Q1 | - TWD | 0.0% |
| 2016 FY | - TWD | -100.0% |
| 2016 Q4 | - TWD | 0.0% |
| 2016 Q3 | - TWD | 0.0% |
| 2016 Q2 | - TWD | 0.0% |
| 2015 Q3 | - TWD | 0.0% |
| 2015 Q4 | - TWD | 0.0% |
| 2015 FY | 12.21 Million TWD | -96.38% |
| 2015 Q1 | - TWD | -100.0% |
| 2015 Q2 | - TWD | 0.0% |
| 2014 Q1 | 333.33 Million TWD | -4.76% |
| 2014 Q4 | 337.88 Million TWD | 0.45% |
| 2014 FY | 337.88 Million TWD | -3.46% |
| 2014 Q3 | 336.36 Million TWD | 0.45% |
| 2014 Q2 | 334.85 Million TWD | 0.45% |
| 2013 Q2 | - TWD | -100.0% |
| 2013 Q4 | 350 Million TWD | 0.0% |
| 2013 FY | 350 Million TWD | 47.93% |
| 2013 Q1 | 79.02 Million TWD | -66.6% |
| 2013 Q3 | - TWD | 0.0% |
| 2012 Q4 | 236.59 Million TWD | 0.0% |
| 2012 Q3 | - TWD | 0.0% |
| 2012 FY | 236.59 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 Q1 | - TWD | 0.0% |
| 2011 Q3 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 Q2 | - TWD | 0.0% |
| 2011 Q1 | - TWD | 0.0% |
| 2011 FY | - TWD | 0.0% |
| 2010 FY | - TWD | 0.0% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 136.36 Million TWD | 99.735% |
| Standard Chem & Pharm CO., LTD. | 222.97 Million TWD | 99.838% |
| Maywufa Company Ltd. | 438.97 Million TWD | 99.918% |
| ScinoPharm Taiwan, Ltd. | 570.23 Million TWD | 99.937% |
| Lotus Pharmaceutical Co., Ltd. | 9.51 Billion TWD | 99.996% |
| YungShin Global Holding Corporation | 241.99 Million TWD | 99.851% |
| PhytoHealth Corporation | 17.46 Million TWD | 97.932% |
| SCI Pharmtech, Inc. | 845.52 Million TWD | 99.957% |
| Formosa Laboratories, Inc. | 2.03 Billion TWD | 99.982% |
| PharmaEssentia Corporation | 954.99 Million TWD | 99.962% |
| Bora Pharmaceuticals Co., LTD. | 3.48 Billion TWD | 99.99% |